Frequently Asked Questions about State Street SPDR S&P Biotech ETF (XBI)

Name: State Street SPDR S&P Biotech ETF (XBI) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does State Street SPDR S&P Biotech ETF (XBI) do?

Accepted Answer

The State Street SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index")Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comp...

Question 2

Is State Street SPDR S&P Biotech ETF (XBI) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of XBI reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if XBI fits their risk profile.

Question 3

What is the current P/E ratio for XBI?

Accepted Answer

As of the latest trading session, State Street SPDR S&P Biotech ETF (XBI) has a trailing P/E ratio of N/A.

Question 4

Who is the CEO of State Street SPDR S&P Biotech ETF?

Accepted Answer

The current Chief Executive Officer of State Street SPDR S&P Biotech ETF is not publicly listed in our current registry.

Question 5

What was XBI's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, State Street SPDR S&P Biotech ETF reported annual revenues of  respectively.

Question 6

Does XBI pay a dividend?

Accepted Answer

State Street SPDR S&P Biotech ETF does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does XBI have?

Accepted Answer

In its latest reporting period, State Street SPDR S&P Biotech ETF generated $N/A in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of State Street SPDR S&P Biotech ETF?

Accepted Answer

The Price-to-Book (P/B) ratio for State Street SPDR S&P Biotech ETF (XBI) is currently N/A.

Question 9

What is the Price-to-Sales (P/S) ratio of XBI?

Accepted Answer

Based on trailing twelve-month data, State Street SPDR S&P Biotech ETF (XBI) trades at a Price-to-Sales (P/S) ratio of N/A.

Question 10

What is State Street SPDR S&P Biotech ETF's Return on Equity (ROE)?

Accepted Answer

State Street SPDR S&P Biotech ETF (XBI) has a Return on Equity (ROE) of N/A, representing its profitability relative to shareholder equity.

XBI

SPDR S&P Biotech ETF $XBI Shares Sold by Flagship Harbor Advisors LLC

Ascent Group LLC Buys New Position in SPDR S&P Biotech ETF $XBI

4,020 Shares in SPDR S&P Biotech ETF $XBI Acquired by Apella Capital LLC

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead